Notice2025-03221

Notice Pursuant to the National Cooperative Research and Production Act of 1993-Rapid Response Partnership Vehicle

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
February 28, 2025

Issuing agencies

Justice DepartmentAntitrust Division

Full Text

<html>
<head>
<title>Federal Register, Volume 90 Issue 39 (Friday, February 28, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 39 (Friday, February 28, 2025)]
[Notices]
[Pages 10949-10950]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-03221]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Rapid Response Partnership Vehicle

    Notice is hereby given that, on January 16, 2025, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership 
Vehicle (``RRPV'') has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Specifically, Fisher BioServices, Inc., Rockville, MD; Landmark 
Vaccines, Ltd., Loughborough, UNITED KINGDOM; Rx Bandz, Locust Valley, 
NY; Zeteo Tech, Inc., Sykesville, MD; BioNet-Asia Co., Ltd, Bangkok, 
KINGDOM OF THAILAND; EmitBio, Inc., Morrisville, NC; Matisse 
Pharmaceuticals, B.V., Geleen, KINGDOM OF THE NETHERLANDS; National 
Institute for Pharmaceutical Technology and Education, Inc., 
Minneapolis, MN; ProtonDx, Ltd., London, UNITED KINGDOM; BioVaxys 
Technology Corp., North Miami, FL; Enplas, Santa Clara, CA; RHEAVITA 
BV, Ghent, BELGIUM; Celltheon, Union City, CA; Chromatan, Inc., Lower 
Gwynedd, PA; Cyrus Biotechnology, Seattle, WA; Eradivir, Inc., West 
Lafayette, IN; InDevR, Inc., Boulder, CO; Kudo Biotechnology, Inc., 
Needham, MA; Panoplia Laboratories, Inc., Cambridge, MA; The Regents of 
the University of California on behalf of its Los Angeles campus, Los 
Angeles, CA; Meridian Medical Technologies LLC, St. Louis, MO; Sarfez 
Pharmaceuticals, Inc., Vienna, VA; Tiba Biotech LLC, Cambridge, MA; 
Ecolab, Inc., Philadelphia, PA; Unicorn Biotechnologies, Inc., Newark, 
NJ; Zipcode Bio, Weston, MA; Acclinate, Inc., Birmingham, AL; Klim-Loc 
Medical, Inc., Carbondale, CO; Primary Diagnostics, Inc. dba 
Primary.Health, San Francisco, CA; Epitogenesis, Inc., Virginia Beach, 
VA; Microbio, Ltd., Brisbane, AUSTRALIA; Aldevron LLC, Fargo, ND; BC3 
Technologies, Inc., Baltimore, MD; Genvax, Ames, IA; Maxim Biomedical, 
Inc., Rockville, MD; Piezo Therapeutics, Inc., Atlanta, GA; Virtu, 
Inc., Leesburg, VA; Digital Infuzion LLC, Rockville, MD; Neolixir, 
Ltd., Perth, AUSTRALIA; and XCMR, Inc., Narberth, PA have been added as 
parties to this venture.
    Also, TFF Pharmaceuticals, Inc., Fort Worth, TX has withdrawn as a 
party to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and RRPV intends to file additional 
written notifications disclosing all changes in membership.
    On January 5, 2024, RRPV filed its original notification pursuant 
to section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to section 6(b) of the Act on 
April 16, 2024 (89 FR 26928).
    The last notification was filed with the Department on October 3, 
2024. The Department of Justice published a notice in the Federal 
Register pursuant to

[[Page 10950]]

section 6(b) of the Act on December 20, 2024 (89 FR 104208).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2025-03221 Filed 2-27-25; 8:45 am]
BILLING CODE P


</pre></body>
</html>
Indexed from Federal Register on February 28, 2025.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.